Resumen

ARREDONDO BRUCE, Alfredo; AMORES CARRATE, Jacqueline  y  GUERRERO MEJIAS, Gustavo. Current and emergent therapies in the non-alcoholic fatty liver . AMC [online]. 2010, vol.14, n.1. ISSN 1025-0255.

The prevalence of obesity and the metabolic syndrome (MS), and subsequently the hepatic manifestation of MS, non alcoholic fatty liver disease (NAFLD), has become a common entity in clinical practice. Most patients with NAFLD face medical complications related to metabolic syndrome in other organs and systems; however, a small but significant group of patients with a most aggressive form of fatty liver: the non alcoholic steatohepatitis (NASH), with the risk of developing cirrhosis and liver cancer. These patients are generally asymptomatic, often this disease goes unrecognized. This is particularly true for NASH, where liver biopsy is currently required to make the diagnosis. Once diagnosed, no treatment has been shown to be universally efficacious and those that show some benefit present side effects. These ones should be directed to decreasing insulin resistance as well as to fight necroinflammation and hepatic fibrosis. The treatment also includes lifestyle modification, surgical therapies, and pharmacotherapy. This review focuses on current and potential future therapies for non-alcoholic steatohepatitis.

Palabras clave : pathy liver; life style; liver cirrhosis; obesity; review literature as topic.

        · resumen en Español     · texto en Español     · Español ( pdf )